Judith Manola

Judith Manola

UNVERIFIED PROFILE

Are you Judith Manola?   Register this Author

Register author
Judith Manola

Judith Manola

Publications by authors named "Judith Manola"

Are you Judith Manola?   Register this Author

100Publications

2752Reads

18Profile Views

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.

J Clin Oncol 2018 06 17;36(16):1556-1563. Epub 2018 Apr 17.

Noah Kornblum, Della F. Makower, and Joseph A. Sparano, Albert Einstein College of Medicine, Bronx; Paula Klein, Mount Sinai Beth Israel Comprehensive Cancer Center, New York, NY; Fengmin Zhao and Judith Manola, Dana-Farber Cancer Institute, Boston, MA; Bhuvaneswari Ramaswamy, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Adam Brufsky, University of Pittsburgh, Pittsburgh; Cristina I. Truica, Penn State Cancer Institute, Hershey; Lori J. Goldstein, Fox Chase Cancer Center, Philadelphia, PA; Phillip J. Stella, Saint Joseph Mercy (Michigan Cancer Consortium), Ann Arbor, MI; Brian Burnette, Saint Vincent Hospital, Green Bay; Timothy R. Wassenaar, Pro Health Care, Waukesha, WI; Melinda Telli, Stanford University School of Medicine, Stanford, CA; Puneet Cheema, Metro-Minnesota Community Oncology Research Consortium, Saint Louis Park, MN; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Gamini S. Soori, Missouri Valley Cancer Consortium, Omaha, NE; Barbara Haley, UT Southwestern Medical Center, Dallas, TX; and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.9331DOI Listing
June 2018

Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.

J Clin Oncol 2016 11 30;34(33):3992-3999. Epub 2016 Sep 30.

Herbert H. Pang and Perry Cheng, School of Public Health, Li Ka Shing Faculty of Medicine, Hong Kong, Special Administrative Region, People's Republic of China; Herbert H. Pang, Xiaofei Wang, Ying Zhang, Thomas E. Stinchcombe, and Harvey J. Cohen, Duke University School of Medicine, Durham, NC; Melisa L. Wong, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco; David Gandara, University of California, Davis Comprehensive Cancer Center, Sacramento, CA; Apar Kishor Ganti, Veterans Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE; Daniel J. Sargent and Sumithra J. Mandrekar, Mayo Clinic, Rochester, MN; Chen Hu, NRG Oncology Statistics and Data Management Center, Philadelphia, PA; Chen Hu, Johns Hopkins University School of Medicine, Baltimore, MD; Mary W. Redman, Fred Hutchinson Cancer Research Center, Seattle, WA; Judith B. Manola, Dana-Farber Cancer Institute, Boston, MA; Richard L. Schilsky, ASCO, Alexandria, VA; Jeffrey D. Bradley, Washington University School of Medicine, St Louis, MO; Alex A. Adjei, Roswell Park Cancer Institute, Buffalo, NY; Suresh S. Ramalingam, The Winship Cancer Institute of Emory University, Atlanta, GA; and Everett E. Vokes, University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.7088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477832PMC
November 2016

Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008.

J Clin Oncol 2016 10;34(29):3544-3553

Chezi Genzel and Jacob M. Rowe, Shaare Zedek Medical Center, Jerusalem, Israel; Chezi Ganzel, Dan Douer, and Martin S. Tallman, Memorial Sloan Kettering Cancer Center; Elisabeth M. Paietta, Montefiore Medical Center; Peter H. Wiernik, St. Luke's-Roosevelt Medical Center, New York, NY; Judith Manola and Ju-Whei Lee, Dana-Farber Cancer Institute, Boston, MA; Hugo F. Fernandez, H. Lee Moffitt Cancer Institute, Tampa, FL; Mark R. Litzow, Mayo Clinic, Rochester, MN; Selina M. Luger, University of Pennsylvania, Philadelphia, PA; Hillard M. Lazarus, University Hospitals Case Medical Center, Cleveland, OH; and Larry D. Cripe, Indiana University Cancer Center, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.5892DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074349PMC
October 2016

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).

J Clin Oncol 2015 Jul 15;33(21):2384-91. Epub 2015 Jun 15.

Keith T. Flaherty, University of Pennsylvania, Philadelphia, PA; Judith B. Manola, Dana-Farber Cancer Institute; David F. McDermott and Michael B. Atkins, Beth Israel Deaconess Medical Center, Boston, MA; Michael Pins, Advocate Lutheran General Hospital, Park Ridge, IL; Janice J. Dutcher, Montefiore Medical Center, Bronx, NY; Daniel J. George, Duke University Medical Center, Durham, NC; Kim A. Margolin, Seattle Cancer Care Alliance, University of Washington, Seattle, WA; and Robert S. DiPaola, Cancer Institute of New Jersey at Hamilton, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.9727DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500832PMC
July 2015

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

J Clin Oncol 2015 Jun 6;33(17):1895-901. Epub 2015 Apr 6.

Melinda L. Telli, Kristin C. Jensen, Shaveta Vinayak, Allison W. Kurian, Jafi A. Lipson, Patrick J. Flaherty, Elizabeth A. Schackmann, Irene L. Wapnir, Robert W. Carlson, Pei-Jen Chang, and James M. Ford, Stanford University School of Medicine, Stanford; Bobbie Head, Marin Specialty Care, Greenbrae, CA; Kirsten Timms, Victor Abkevich, Julia E. Reid, and Anne-Renee Hartman, Myriad Genetics, Salt Lake City, UT; Joseph A. Sparano, Albert Einstein College of Medicine, New York, NY; Lori J. Goldstein, Fox Chase Cancer Center, Philadelphia, PA; Barbara Haley, University of Texas Southwestern Medical Center, Dallas, TX; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; and Judith Manola, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.0085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451172PMC
June 2015

Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors.

Psychooncology 2015 May 14;24(5):523-32. Epub 2014 Jun 14.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.3606DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265573PMC
May 2015

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.

Clin Genitourin Cancer 2015 Apr 22;13(2):113-23. Epub 2014 Oct 22.

Medical Oncology, Dana-Farber Cancer Institute and Internal Medicine, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418946PMC
April 2015

Using patient-reported outcomes to assess and improve prostate cancer brachytherapy.

BJU Int 2014 Oct 22;114(4):511-6. Epub 2014 May 22.

Massachusetts General Hospital Cancer Center, Boston, MA, USA; Continuum Cancer Centers of New York, New York, NY, USA; Albert Einstein School of Medicine, New York, NY, USA; Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.12464DOI Listing
October 2014

Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.

Eur J Cancer 2014 Mar 2;50(5):981-6. Epub 2014 Jan 2.

Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States; Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02215, United States; Ludwig Center and Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.11.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242716PMC
March 2014

Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).

J Thorac Oncol 2013 Aug;8(8):1075-83

Department of Medical Oncology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182937317DOI Listing
August 2013

Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: a cooperative group correlative study.

Clin Cancer Res 2013 May 26;19(9):2528-40. Epub 2013 Feb 26.

Departments of Otolaryngology-Head, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642232PMC
May 2013

When bad things happen to good studies.

J Clin Oncol 2011 Sep 15;29(26):3497-9. Epub 2011 Aug 15.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.37.1393DOI Listing
September 2011

Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer.

Cancer 2011 Jan 27;117(1):96-102. Epub 2010 Aug 27.

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25291DOI Listing
January 2011

Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer.

Radiother Oncol 2010 Jun 27;95(3):350-8. Epub 2010 Apr 27.

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2010.03.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883632PMC
June 2010

Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients.

Integr Cancer Ther 2010 Jun;9(2):158-67

Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1534735409360666DOI Listing
June 2010

Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.

Ann Surg Oncol 2010 Feb 7;17(2):407-15. Epub 2009 Nov 7.

Department of Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-009-0784-yDOI Listing
February 2010

The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins.

Clin Cancer Res 2009 Dec;15(24):7658-7665

Authors' Affiliations: Johns Hopkins University and Greater Baltimore Medical Center, Baltimore, Maryland; Dana-Farber Cancer Institute, Boston, Massachusetts; Pennsylvania State Hershey Medical Center, Hershey, Pennsylvania; Fox Chase Cancer Center, Philadelphia, Pennsylvania; University of Miami/Sylvester Comprehensive Cancer Center, Miami, Florida; University of Kentucky, Lexington, Kentucky; and Department of General and Environmental Physiology, Centre of Excellence in Comparative Genomics (CEGBA), University of Bari, Bari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2842212PMC
December 2009

Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.

Eur J Cancer 2009 Nov 31;45(16):2818-24. Epub 2009 Jul 31.

Department of Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2009.06.030DOI Listing
November 2009

Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614.

Arch Otolaryngol Head Neck Surg 2009 Sep;135(9):851-8

Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archoto.2009.123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846171PMC
September 2009

Effects of a music therapy intervention on quality of life and distress in women with metastatic breast cancer.

J Soc Integr Oncol 2006 ;4(3):116-24

Music Therapy Department, Berklee College of Music, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2310/7200.2006.014DOI Listing
June 2009

Treatment 'mismatch' in early prostate cancer: do treatment choices take patient quality of life into account?

Cancer 2008 Jan;112(1):61-8

Center for Outcomes Research, MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23138DOI Listing
January 2008

CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.

AJR Am J Roentgenol 2007 Dec;189(6):W324-30

Massachusetts College of Pharmacy and Health Sciences, 4 Brook Rd., Unit 11, Salem, NH 03079, USA.

View Article

Download full-text PDF

Source
http://www.ajronline.org/doi/10.2214/AJR.07.2496
Publisher Site
http://dx.doi.org/10.2214/AJR.07.2496DOI Listing
December 2007

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group.

Cancer 2007 Aug;110(4):759-63

Department of Solid Tumor Oncology and the Urologic Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22839DOI Listing
August 2007

Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.

J Urol 2007 Jun;177(6):2146-50

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2007.01.119DOI Listing
June 2007

Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand.

J Urol 2006 Oct;176(4 Pt 1):1558-63; discussion 1563-4

Center for Outcomes Research, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston 02114-2696, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S002253470601450
Publisher Site
http://dx.doi.org/10.1016/j.juro.2006.06.067DOI Listing
October 2006

Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.

Urology 2006 Jun;67(6):1235-40

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2006.01.006DOI Listing
June 2006

Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.

Eur J Cancer 2006 May 28;42(7):864-70. Epub 2006 Feb 28.

Dana-Farber Cancer Institute, Massachusetts General Hospital, Ludwig Center for Cancer Research at Dana-Farber/Harvard, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2005.12.010DOI Listing
May 2006

Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy.

Urol Oncol 2005 Jul-Aug;23(4):230-7

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2005.02.005DOI Listing
November 2005

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.

Clin Cancer Res 2005 Jul;11(14):5233-40

Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-05-0299DOI Listing
July 2005

The telomerase reverse transcriptase regulates chromatin state and DNA damage responses.

Proc Natl Acad Sci U S A 2005 Jun 31;102(23):8222-7. Epub 2005 May 31.

Department of Medical Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0503095102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1149439PMC
June 2005

A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

Clin Cancer Res 2005 Jan;11(1):284-9

Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
January 2005

Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis.

J Urol 2004 Sep;172(3):1134-9

Department of Molecular Biosciences, and Biotechnology Centre of Oslo, University of Oslo, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.ju.0000136526.78535.b8DOI Listing
September 2004

Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population.

Clin Prostate Cancer 2004 Sep;3(2):98-103

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/cgc.2004.n.019DOI Listing
September 2004

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

JAMA 2004 Aug;292(7):821-7

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Mass 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.292.7.821DOI Listing
August 2004

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.

Nat Med 2004 Jun 23;10(6):594-601. Epub 2004 May 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm1052DOI Listing
June 2004

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.

Cancer 2004 Apr;100(8):1639-45

Department of Hematology/Oncology and Urologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20123DOI Listing
April 2004

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

Clin Cancer Res 2004 Mar;10(5):1670-7

University of Pittsburgh Medical Center, Department of Medicine, Pittsburgh, Pennsylvania 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.ccr-1103-3DOI Listing
March 2004

Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.

Urology 2004 Feb;63(2):327-32

Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S009042950301064
Publisher Site
http://dx.doi.org/10.1016/j.urology.2003.09.059DOI Listing
February 2004

Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer.

Clin Prostate Cancer 2003 Dec;2(3):177-80

Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/cgc.2003.n.027DOI Listing
December 2003

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.

Urology 2003 Jul;62(1):99-104

Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0090-4295(03)00145-6DOI Listing
July 2003

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.

Cancer 2003 Jun;97(11):2743-7

Department of Hematology/Oncology and the Urologic Institute, Cleveland Clinic Foundation, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.11413DOI Listing
June 2003

Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.

Am J Clin Oncol 2003 Jun;26(3):312-6

Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.COC.0000020921.08768.1FDOI Listing
June 2003

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.

Cancer 2002 Nov;95(9):1864-8

Department of Hematology Oncology, Massachusetts General Hospital, Boston 02114, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.10844
Publisher Site
http://dx.doi.org/10.1002/cncr.10844DOI Listing
November 2002

Phase III study of ibuprofen versus placebo for radiation-induced genitourinary side effects.

Int J Radiat Oncol Biol Phys 2002 Sep;54(1):191-4

Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0360-3016(02)02907-3DOI Listing
September 2002

Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis.

Int J Radiat Oncol Biol Phys 2002 Aug;53(5):1106-10

Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0360-3016(02)02885-7DOI Listing
August 2002